Selling the Story of a Discovery

Magnus Höök, a professor at Texas A&M, worked for more than 20 years perfecting an antibody that attacks protein adhesins on bacterial surfaces. But when Höök and his colleagues sought to move their trademark proteins into the market, he says his "lack of knowledge" surprised him. "You start out thinking this is a cool idea, and it would be useful," Höök relates. Höök is a director at Inhibitex Inc., an Alpharetta, Ga.-based company that is now testin

Written byPaula Park
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Many scientists loathe any association with such commercial considerations Höök observes, and indeed, even Lita Nelson, director of the Technology Licensing Office of the Massachusetts Institute of Technology, takes pains to distance academic enterprise from pure entrepreneurship. "Most universities see technology transfer primarily as a way of getting very early stage technology invested in," she says. "They recognize the high risk. It is not primarily a money-making proposition for most universities, ... but instead a way of getting their funding for basic research into practical use by the public."

Editor's Note: Parts 2 and 3 of Taking a Discovery to Market will appear in the Nov. 26 and Dec. 10 issues.

But product development requires private finance. Before Höök could get development funds, he had to replace his focus on the basic research with an emphasis on the story, the market-based justification of investment in an innovation. That story can ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies